Poster HER2-low presented at ASCO2023

June 4, 2023

•

7 min read

Share this post

Our #ASCO2023 poster on HER2-low was selected for oral presentation by session chair Prof. David Rimm (Yale University School of Medicine). In his discussion he highlighted AI as an essential means to score HER2 in the future. The paper “AI-based HER2-low IHC scoring in breast cancer across multiple sites, clones and scanners” was written together with PD Dr. med. habil. Ramona Erber, Arndt Hartmann, Evgeny / Евгений Dr. Minin / Минин, Hanna Hübner, Carolin Schmidt, Ralf Banisch, Stefan Gunther, Patrick Frey, Tobias Lang, Matthias Ruebner, Peter Andreas Fasching, Niklas Abele, Andreas Mamilos. Thank you to all contributors!

Live Publication Link

Share this article

Related reading

ihc

8 min read

Enhancing HER2 IHC Interpretation in Breast Cancer with AI Assistance: Focus on Ultralow Expression in a Multicenter Study across Asia

Emerging therapies for HER2-low and -ultralow breast cancer emphasize the need for precise and consistent HER2 IHC scoring. However, interpretation remains challenging due to staining variability and subjective thresholds. AI tools may improve diagnostic accuracy and reproducibility, yet real-world data across multiple centers - especially for HER2-ultralow expression - to date is sparse.

ihc

8 min read

Quantitative and qualitative evaluation of an AI-assistance software for PD-L1 TPS assessment in non-small cell lung cancer (NSCLC)

In summary, the AI software investigated was found to increase both accuracy and interobserver agreement of pathologists in PD-L1 NSCLC TPS scoring and was reported to be helpful and user-friendly for application in a routine diagnostic workflow.

ihc

8 min read

Augmenting HER2 IHC Assessment, Including HER2 Ultralow Scoring, in Breast Cancer with AI Support: A Multinational Observational Study

The emergence of novel therapies targeting low and ultralow HER2 expression in breast cancer stresses the need for accurate, reproducible HER2 immunohistochemistry (IHC) assessment.

ihc

8 min read

Al-based accurate PD-L1 IHC assessment in non-small cell lung cancer across multiple sites and scanners

Using challenging validation data from three institutions and four scanners, ROI scoring with the support of our Al. PD-L1 quantifier showed high agreement with pathologists, while significantly reducing assessment time.

ihc

8 min read